Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Apr 13;6(1):e20-e22.
doi: 10.1016/j.jccase.2012.03.011. eCollection 2012 Jul.

5-Fluorouracil-induced coronary thrombosis: A case report and review of the literature

Michael F Sorrentino  1 , Alexander G Truesdell  2
Affiliations
Case Reports

5-Fluorouracil-induced coronary thrombosis: A case report and review of the literature

Michael F Sorrentino et al. J Cardiol Cases. .

Abstract

5-Fluorouracil (5-FU) is a key component in the treatment of many gastrointestinal tract adenocarcinomas. Despite its proven therapeutic efficacy, this chemotherapeutic agent also possesses several associated cardiac toxicities, including coronary vasospasm and coronary thrombosis. We report a case of acute coronary syndrome with thrombotic subtotal coronary artery occlusion in the setting of home 5-FU infusion highlighting the importance of careful pre-administration cardiac evaluation and close monitoring during drug administration.

Keywords: 5-Fluorouracil; Acute coronary syndrome; Cardiotoxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Angiogram demonstrating thrombotic subtotal occlusion of the left circumflex coronary artery on right anterior oblique caudal projection. (B) Angiogram in the same projection following percutaneous coronary intervention with a bare metal stent.
See this image and copyright information in PMC

References

    1. Kosmas C., Kallistratos M.S., Kopterides P., Syrios J., Skopelitis H., Mylonakis N., Karabelis A., Tsavaris N. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134:75–82. - PubMed
    1. Labianca R., Beretta G., Clerici M., Frascini P., Luporini G. Cardiac toxicity of 5-flurouracil: a study on 1083 patients. Tumori. 1982;68:505–510. - PubMed
    1. Becker K., Erckenbrecht J., Haussinger D., Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57:475–484. - PubMed
    1. Rezkalla S., Kloner R.A., Ensley J., al-Sarraf M., Revels S., Olivenstein A., Bhasin S., Kerpel-Fronious S., Turi Z.G. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol. 1989;7:509–514. - PubMed
    1. Stewart T., Pavlakis N., Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40:303–307. - PubMed

Publication types

LinkOut - more resources